Unmet Need for Biomarkers in Kennedy Disease

Spinal and bulbar muscular atrophy, also known as Kennedy disease, is an X-linked, slowly progressive neuromuscular disorder affecting adult males. Patients experience progressive proximal limb weakness, fasciculations, muscle atrophy, and bulbar impairment. Because motor neuron loss occurs gradually over decades, evaluating drug efficacy in clinical trials poses significant challenges. Traditional clinical endpoints rely on functional rating scales and walking endurance tests. However, these instruments often lack the sensitivity needed to detect subtle pathological changes over standard six to twelve-month trial periods. Consequently, researchers urgently need objective, non-invasive imaging biomarkers that reflect ongoing tissue degeneration before functional decline becomes apparent.

Quantitative magnetic resonance imaging offers a powerful solution to this bottleneck. By directly measuring tissue composition, quantitative imaging captures muscle fat replacement and tissue volume loss accurately. Implementing quantitative muscle MRI in SBMA research provides objective metrics that avoid the subjective variability seen in functional testing. Furthermore, establishing responsive radiological biomarkers accelerates drug development by enabling shorter, more efficient clinical trials with smaller patient cohorts while maintaining strong statistical power.

Quantifying Disease Progression with Whole-Body Dixon Imaging

To evaluate quantitative imaging, researchers conducted a longitudinal study involving patients with genetically confirmed disease and baseline muscle fat replacement. Participants underwent imaging assessments and clinical evaluations at baseline and every six months for up to eighteen months. Investigators utilized whole-body Dixon imaging protocols, analyzing nineteen bilateral muscle groups through automated image processing. This approach enabled precise quantification of lean muscle volume, muscle fat fraction, and muscle fat infiltration across whole-body composite measures and regional anatomical segments.

The trial enrolled twenty-six patients with a mean age of fifty-seven years. Baseline testing revealed variable physical impairment across functional scales and walking tests. By calculating standardized response mean values, researchers evaluated parameter responsiveness over twelve months. The whole-body Dixon protocol generated reproducible quantitative data across multiple muscle groups without observer bias. Consequently, this longitudinal framework confirmed that magnetic resonance techniques reliably track subtle structural changes in skeletal muscle, even when patient functional scores remain unchanged over short follow-up periods.

Key Findings on Lean Muscle Volume and Fat Infiltration

The longitudinal results demonstrated biological changes in skeletal muscle structure over twelve months. Patients exhibited a mean reduction in whole-body lean muscle volume of 4.38 percent, with a standardized response mean of negative 1.76. Concurrently, whole-body muscle fat fraction increased by an average of 2.49 percentage points, producing a standardized response mean of 1.81. Additionally, whole-body muscle fat infiltration showed a statistically significant increase of 0.79 percentage points, corresponding to a standardized response mean of 1.55. These measurements highlight rapid structural remodeling within diseased muscle tissues.

Importantly, these standardized response mean values demonstrate high responsiveness to disease progression compared to standard functional tools. While physical performance metrics changed minimally over twelve months, quantitative magnetic resonance parameters showed clear, statistically significant changes. Regional analyses further revealed that lower limb musculature, particularly thigh and calf groups, experienced accelerated fat replacement relative to upper body groups. Thus, quantifying muscle fat fraction and lean volume offers superior sensitivity for tracking disease activity during short observation periods.

Clinical Correlations with Functional Rating Scales

Establishing clinical relevance requires demonstrating that quantitative imaging parameters correlate with established functional assessment scales. Investigators evaluated statistical relationships between imaging metrics and clinical tools, including the functional rating scale and two-minute walk test. Baseline whole-body lean muscle volume correlated positively with functional rating scores. Conversely, whole-body muscle fat fraction and muscle fat infiltration displayed clear inverse correlations with clinical performance. These relationships confirm that quantitative imaging accurately reflects overall physical impairment and functional capacity in affected individuals.

Furthermore, regional composite measures showed even stronger clinical associations than whole-body parameters. Specifically, quantitative metrics derived from thigh muscle groups demonstrated prominent correlations with walking distance and motor function scores. Patients with higher fat replacement in thigh musculature exhibited significantly shorter walk test distances and lower functional scores. This regional specificity aligns with clinical practice, as proximal leg weakness directly affects mobility. Therefore, combining quantitative magnetic resonance assessments with physical evaluations provides a comprehensive profile of disease burden in patient management.

Role of Muscle MRI in SBMA Clinical Trial Design

High responsiveness and strong clinical correlation establish quantitative imaging as a transformative tool for future interventional studies. Conducting clinical trials in rare neuromuscular diseases involves significant challenges, including small patient numbers and slow disease progression. Traditional endpoints require long observation periods and large sample sizes to demonstrate treatment efficacy. However, the high standardized response mean values observed with quantitative imaging parameters significantly reduce required sample sizes and study durations needed to detect therapeutic efficacy.

By using lean muscle volume or fat fraction as clinical trial endpoints, investigators can design focused, cost-effective studies. Quantitative magnetic resonance imaging provides an objective readout unaffected by patient effort, fatigue, or evaluator subjectivity. Additionally, early detection of treatment response or disease stabilization allows researchers to make timely decisions regarding therapeutic candidates. Integrating quantitative muscle MRI in SBMA protocols accelerates drug discovery, offering renewed hope for developing effective disease-modifying therapies for patients.

Future Directions for Imaging Outcomes in Rare Neuromuscular Disorders

The validated imaging framework established in this study paves the way for broader application across neuromuscular research. Beyond volume and fat fraction measurements, future studies may incorporate advanced imaging sequences like diffusion tensor imaging and spectroscopy. These specialized modalities evaluate muscle microarchitecture, membrane integrity, and metabolism, offering deeper mechanistic insights into disease progression. Combining quantitative structural imaging with fluid biomarkers could establish a comprehensive multi-modal monitoring protocol for patient care.

Furthermore, expanding automated image analysis platforms will facilitate widespread adoption across clinical trial sites. Standardized imaging protocols and automated segmentation tools reduce processing time and eliminate analytical bias, ensuring reproducible results across scanner platforms. As clinical trial networks adopt these validated radiological endpoints, regulatory agencies will increasingly recognize quantitative imaging surrogates for drug approval. Ultimately, incorporating advanced quantitative imaging into clinical research enhances trial precision and accelerates targeted therapy development.

Frequently Asked Questions

What is the primary advantage of quantitative muscle MRI in SBMA?

Quantitative muscle MRI provides an objective, highly sensitive measure of muscle fat replacement and volume loss. Unlike functional rating scales, which can vary based on patient fatigue or motivation, quantitative MRI detects subtle structural changes over six to twelve months, making it an ideal biomarker for clinical trials.

How do lean muscle volume and fat fraction change over twelve months?

In longitudinal studies, patients showed an average decrease of 4.38 percent in whole-body lean muscle volume over twelve months. Concurrently, whole-body muscle fat fraction increased by 2.49 percentage points, demonstrating high responsiveness and consistent disease progression even when clinical functional scores remained stable.

Why are functional rating scales alone insufficient for early SBMA trials?

SBMA is a slowly progressive condition where physical function changes gradually over years. Functional rating scales often lack the sensitivity required to detect minor changes within standard trial durations. Quantitative imaging captures ongoing structural muscle damage before overt functional decline occurs, enabling shorter and smaller clinical trials.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or clinical management. Refer to the latest local and national guidelines for clinical practice.

References

1. Grunseich C et al. Muscle MRI as an Imaging Biomarker of Muscle Damage in Patients With Spinal and Bulbar Muscular Atrophy. Neurology. 2026 Aug 11. doi: 10.1212/WNL.0000000000218309. PMID: 42479997.


2. Fionda L et al. Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study. J Neurol. 2024;271(8):5120-5130.